

**"EXPRESS MAIL CERTIFICATE"**  
**"EXPRESS MAIL" MAILING LABEL NUMBER EV332944764US**  
**DATE OF DEPOSIT November 25, 2003**

Attorney Docket No. P31831C2

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**


Applicant: Stephen Alistair Smith November 25, 2003  
Serial No.: Not Yet Assigned Group Art Unit No.: Not Yet Assigned  
Filed: Herewith Examiner: Not Yet Assigned  
For: TREATMENT OF DIABETES WITH ROSIGLITAZONE AND INSULIN

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER**  
**37 C.F.R. §1.97(b)**

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,



Kathryn L. Sieburth  
Attorney for Applicants  
Registration No. 40,072

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5012  
Facsimile (610) 270-5090

N:\kls\cases\p31831c2\IDS Letter.doc

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31831C2	SERIAL NO. Not Yet Assigned
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		FILING DATE Herewith	GROUP Not Yet Assigned

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Avandia Drug Profile. <i>PDR Health Website – www.pdrhealth.com</i>
	Weinstock, et al. <i>Int'l. J. Exp. Clin. Pharmacol.</i> , 54: 169-178 (1997).
	Iwamoto, et al., "Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled By Sulphonylurea Therapy Alone". <i>Diabetic Medicine</i> , 13: 365-370 (1995).
	Alberti, et al., "A Desktop Guide for the Management of Non-Insulin Dependent Diabetes Mellitus (NIDDM): An Update". <i>Diabetic Medicine</i> , 11: 899-909 (1994).
	Iwamoto. "Usage of New Oral Anti-Diabetic Drugs". <i>Klinika</i> , 22(6) pp. 445-450 (1995).
	Nakano, et al., "Clinical Evaluation of a New Oral Hypoglycemic Drug, CS-045, on Daily Profile of Blood Glucose in Patients with Non-Insulin Dependent Diabetes Mellitus". <i>Rinsyou Iyaku (Clinical Medicine)</i> , 9th Vol., Supp. 3: pp. 151-164 (1993).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31831C2	PRED. SERIAL NO. 09/928,326
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE August 13, 2001	PRED. GROUP 1617

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,895,862	1/23/90	Alessi, et al.	514	360	
	5,068,342	11/26/91	Zask, et al.	548	183	
	US20020177612	11/28/02	Grannett, et al.	514	340	
	6,291,495	9/18/01	Rieveley	514	369	
	6,153,632	11/28/00	Rieveley	514	369	
	5,952,356	9/14/99	Ikeda, et al.	514	340	
	6,150,383	11/21/00	Ikeda, et al.	514	342	
	6,031,004	2/29/00	Timmins, et al.	514	635	
	6,271,243	8/7/01	Ikeda, et al.	514	342	
	5,965,584	10/12/99	Ikeda, et al.	514	342	

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes No	
	WO 97/10819	3/1997	PCT				
	WO 95/07694	3/1995	PCT				
	WO 97/05875	2/1997	PCT				
	WO 97/17975	5/22/97	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Connor, et al., "Antidiabetic Efficacy of BRL 49653, a Potent Orally Active Insulin Sensitizing Agent, Assesses in the C57BL/KsJ <i>db/db</i> Diabetic Mouse by Non-Invasive <sup>1</sup> H NMR Studies in Urine". <i>J. Pharm. Pharmacol.</i> , 49(3): 336-344 (1997) (XP002080751)
	Lefebvre, et al., "Improving the Action of Insulin". <i>Clin. Invest. Med.</i> , 18(4): 340-347 (1995).
	Skyler, et al., "Insulin Therapy in Type II Diabetes". <i>Postgraduate Medicine</i> , 101(2): 85-96 (1997).
	Neyrolles, et al., "New Therapeutic Agents of Non-Insulin-Dependent Diabetes". <i>Ann. D'Endocrinologie</i> , 59(2): 67-77 (1998). (XP002080748)
	Iwamoto, et al., "Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM". <i>Diabetes Cure</i> , 14(11): 1083-1086 (1991).
	Hotta. "How to Select and Use Oral Hypoglycemic Agents". <i>Tonyoby</i> , Update 10, pp. 68-77, April 1994 (with translation).
	Fukuda, et al., "A Clinical Study of a New Hypoglycemic Agent, Troglitazone, in Type 2 Diabetes Patients who are Unsatisfactorily-Controlled with Insulin". <i>Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)</i> , 11(10): 2055-2060 (1995) (Translation).
	Hofmann, et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers". <i>Diabetes Care</i> , 15(8): 1075-1078 (1992).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P31831C2	PRED. SERIAL NO. 09/928,326
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Stephen Alistair Smith	
		PRED. FILING DATE August 13, 2001	PRED. GROUP 1617

## U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,297,269	10/2001	Hulin, et al.	514	414	

## FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Vialettes, et al., "Pharmacological Approach in the Treatment of Insulin Resistance". <i>Horm. Res.</i> , <u>38</u> : 51-56 (1992).
	Harold E. Lebovitz. "Stepwise and Combination Drug Therapy for the Treatment of NIDDM". <i>Diabetes Care</i> , <u>17</u> (12): 1542-1544 (1994).
	Weinstock, et al., "Pioglitazone: In Vitro Effects on Rap Hepatoma Cells and In Vivo Liver Hypertrophy in KKA <sup>y</sup> Mice". <i>Pharmacology</i> , <u>54</u> : 169-178 (1997).
	Gareth Williams. "Management of Non-Insulin-Dependent Diabetes Mellitus". <i>The Lancet</i> , <u>343</u> : 95-100 (1994).
	Lehmann, et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor $\gamma$ (PPAR $\gamma$ )". <i>J. Biol. Chem.</i> , <u>270</u> (22): 12953-12956 (1995).
	Donnelly, et al., "Drugs and Insulin Resistance: Clinical Methods of Evaluation and New Pharmacological Approaches to Metabolism". <i>Br. J. Clin. Pharmacol.</i> , <u>37</u> : 311-320 (1994).
	Lefebvre, et al., "Improving the Action of Insulin". <i>Clin. Invest. Med.</i> , <u>18</u> (4): 340-347 (1995). (XP002080750)
	Foot, et al., "Improved Metabolic Control by Addition of Troglitazone to Glibenclamide Therapy in Non-Insulin Dependent Diabetics". <i>Diabetologia</i> , <u>38</u> (S1): A44 (1995).
	Whitcomb, et al., "Thiazolidinediones". <i>Exp. Opin. Invest. Drugs</i> , <u>4</u> (12): 1299-1309 (1995).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\kls\cases\p31831c2\predecessor prior art 1449 form.doc